MENLO PARK, Calif.--(BUSINESS WIRE)--July 24, 2006--Depomed, Inc. (Nasdaq:DEPO - News) announced today that the company is in discussions with Esprit Pharma regarding the $10 million license fee due Depomed under its agreement with Esprit for marketing ProQuin® XR. The license fee payment was not made on July 21, 2006, the actual due date per the July 2005 agreement entered into by the two companies.
